Johnson & Johnson Lifts 2025 Outlook

Johnson & Johnson (JNJ 6.09%) reported Q2 2025 earnings on July 16, 2025, posting sales of $23.7 billion (up 4.6%), with adjusted EPS of $2.77 and net earnings of $5.5 billion. Management raised full-year 2025 sales guidance by $2 billion and adjusted EPS guidance by $0.25, citing robust operational momentum across innovative medicine and medtech. The following insights examine how strategic execution, diversified growth drivers, and pipeline achievements are shaping the company's long-term investment profi ...